Azopharma Completion of New Cytotoxic Manufacturing Suites for Clinical Trial Materials
Wednesday, 01 July 2009
HOLLYWOOD, Fla. - Azopharma Product Development Group, is pleased to announce the completed expansion of its cGMP cytotoxic and highly-potent compound facilities at its South Florida-Hollywood location. The expansion adds an additional 7,000 sq. ft. of space to Azopharma's current capacity and includes 3 manufacturing suites with dedicated equipment, analytical instrumentation and staff. The expansion further strengthens Azopharma's position as an industry leader in manufacturing and processing of cytotoxic and highly potent compounds for pharmaceutical development.
The cytotoxic suites join eleven new cGMP suites, two aseptic cGMP suites, and two explosion proof suites completed earlier this year and brings Azopharma's manufacturing suite total to 29. Mr. Phil Meeks, CEO of Azopharma comments, "We are excited to see our new cytotoxic suites up and running. These suites are key to maintaining our position as a leader in total product development. Our capabilities are unique within the industry based on the depth and scope of our development capabilities which range from discovery to commercialization." The manufacturing suite expansion is complimented by the addition of state-of-the-art equipment including the MG Futura Capsule Filler, Bausch & Strobel Aseptic Filling Isolator and XcelodoseTM powder microdosing system.
Azopharma Product Development Group Includes:
- Azopharma Contract Pharmaceutical ServicesTM - Integrated product development including synthesis, analysis, formulation and CTM manufacturing for all dosage forms.
- AniClin Preclinical ServicesTM - Preclinical services in support of early product development.
•AvivoClin Clinical ServicesTM - Human clinical pharmacology and monitoring services for Phase I-III clinical trials.
Azopharma Product Development Group, The Total Product Development Company TM, is FDA registered, DEA approved and client audited on a regular basis. In product development, it comes down to the right people, their commitment and application of experience. Partnering with Azopharma provides customers with the confidence of assured success. We welcome visits to our South Florida facilities as well as our other sites to conduct audits or meet with our pharmaceutical scientists to outline a study that meets your specific needs. Contact one of our scientists at [email protected] or 954-433-7480.
Contact Phil Meeks, CEO Azopharma Product Development Group 2 Oakwood Boulevard, Suite 170 Hollywood, FL 33020 Phone: 954-433-7480 www.azopharma.com